Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage

Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage

Arcus Biosciences shares rose 4.8% to $22.32 Tuesday after Goldman Sachs upgraded the stock to “Buy” and raised its price target. The move followed early Phase 1 data for lead drug casdatifan showing response rates of 31% alone and 46% in combination for advanced kidney cancer. Arcus plans to present at the J.P. Morgan Healthcare Conference on Wednesday. The company reported $1 billion in cash and funding into late 2028.
13 January 2026
·
Roblox stock jumps as BMO flags a breakout game and Feb. 5 earnings loom (RBLX)

Roblox stock jumps as BMO flags a breakout game and Feb. 5 earnings loom (RBLX)

Roblox shares rose 8% to $83.09 in midday New York trading Tuesday, after touching $83.98 and trading as low as $76.05. The company will report fourth-quarter and full-year 2025 results after the bell on Feb. 5. BMO reiterated an Outperform rating, citing strong early performance of a new game. New York’s governor is pushing for stricter online gaming rules affecting Roblox, The Verge reported.
13 January 2026
····
Solaris Energy Infrastructure stock jumps 6% as traders chase data-center power play — what to watch next for SEI

Solaris Energy Infrastructure stock jumps 6% as traders chase data-center power play — what to watch next for SEI

Solaris Energy Infrastructure shares rose 6.4% to $54.64 in midday trading Tuesday, near a 52-week high. Analyst Bobby Brooks raised his price target to $70, citing 900 megawatts of open capacity likely to be contracted in early 2026. Solaris is scaling toward 2.2 gigawatts of operated power, with Power Solutions expected to drive future earnings. Next earnings report is estimated for Feb. 19, 2026.
13 January 2026
···
Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics shares surged about 14% midday Tuesday after a recent SEC filing revealed a $100 million upfront patent license deal with Roche’s Genentech for an oral GLP-1 drug. The stock rose to $79.24, up $9.88 from Monday’s close, as investors re-evaluated obesity-drug makers during the J.P. Morgan Healthcare Conference.
13 January 2026
····
Kennametal stock jumps on Jefferies upgrade as tungsten prices hit fresh highs

Kennametal stock jumps on Jefferies upgrade as tungsten prices hit fresh highs

Kennametal shares rose 8.4% to $33.32 midday Tuesday after Jefferies upgraded the stock and raised its price target to $40, citing a sharp spike in tungsten prices. Tungsten benchmark prices in China hit 725,000 yuan per ton, renewing concerns over raw-material costs. The stock’s rally pushed it above recent targets from UBS and Morgan Stanley. Investors await Kennametal’s earnings report on Feb. 4 for margin and demand updates.
13 January 2026
·
Scorpio Tankers stock jumps nearly 9% on net-cash update as investors eye a February catalyst

Scorpio Tankers stock jumps nearly 9% on net-cash update as investors eye a February catalyst

Scorpio Tankers shares surged nearly 9% to $59.85 by midday Tuesday after the company reported a net cash position of $164.7 million, outstripping its debt. A U.S. filing showed Scorpio agreed to sell the LR2 tanker STI Kingsway for $57.5 million, with closing expected in early 2026. Investors are watching the timing of vessel sales and related cash flows. Peers Frontline and International Seaways rose about 3%.
13 January 2026
··
Option Care Health (OPCH) stock jumps nearly 10% on early Q4 results, 2026 outlook and a bigger buyback

Option Care Health (OPCH) stock jumps nearly 10% on early Q4 results, 2026 outlook and a bigger buyback

Option Care Health shares rose nearly 10% to $35.16 Tuesday after the company released preliminary Q4 results and doubled its share buyback authorization to $1.0 billion. The company projects Q4 net revenue of $1.46–$1.47 billion and adjusted EPS of $0.46–$0.49. A Citizens analyst raised the price target to $38, citing easing Stelara-related risk after 2026.
13 January 2026
··
TransMedics stock jumps as SEC filing details $23.9 million-a-year lease for new Massachusetts HQ

TransMedics stock jumps as SEC filing details $23.9 million-a-year lease for new Massachusetts HQ

TransMedics shares rose about 8% Tuesday after the company disclosed a lease for nearly 498,000 square feet in Somerville, Massachusetts, to serve as its new global headquarters. The lease begins in early 2028 with base rent starting at $23.9 million per year and an $18 million security deposit. The stock touched $151.70 before closing at $145.68. State and local incentives could total up to $18 million if hiring targets are met.
13 January 2026
·
POSCO Holdings stock jumps 12% after $700 million bond sale — what investors watch next

POSCO Holdings stock jumps 12% after $700 million bond sale — what investors watch next

POSCO Holdings’ U.S.-listed shares surged 12% to $60.39 Tuesday after the company raised $700 million in a two-part global bond sale, drawing $6.6 billion in bids. The bonds, split into five- and ten-year tranches, will mainly refinance existing debt. Most demand came from Asian investors. Traders now await POSCO’s Jan. 29 earnings report and further refinancing moves.
13 January 2026
·
KEPCO stock jumps 9% after broker lifts target to 70,000 won — what to watch next for 015760

KEPCO stock jumps 9% after broker lifts target to 70,000 won — what to watch next for 015760

Korea Electric Power shares jumped 9.2% to close at 55,700 won Tuesday, their highest in a year, after NH Investment raised its target price to 70,000 won citing profit recovery and U.S. nuclear market potential. Investors are watching for tariff decisions, export-control talks, and the next earnings report. The KOSPI index also hit a new record, closing up 1.5% at 4,692.6.
13 January 2026
··
Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

Moderna shares jumped 11.7% to $37.81 after the company raised its 2025 sales outlook to about $1.9 billion and cut its operating expense forecast by $200 million. The company reiterated its 2026 growth target and said it does not expect flu or COVID-flu shots to be approved for the 2026 season. Investors await Feb. 13 results and early-2026 cancer vaccine data with Merck.
13 January 2026
··
TTM Technologies stock surges nearly 20% as TTMI draws fresh attention at Needham Growth Conference

TTM Technologies stock surges nearly 20% as TTMI draws fresh attention at Needham Growth Conference

TTM Technologies shares jumped 19% to $92.84 Tuesday morning, leading electronics stocks as traders watched for updates from the Needham Growth Conference in New York. The company’s latest quarter showed net sales up 22% year-over-year to $752.7 million. Wall Street price targets lag behind the current rally. Investors await results from conference meetings and the next earnings report, likely in early February.
13 January 2026
·
Intel stock pops after KeyBanc upgrade, $60 target as AI server demand tightens

Intel stock pops after KeyBanc upgrade, $60 target as AI server demand tightens

Intel shares jumped 6.4% to $46.88 Tuesday after KeyBanc upgraded the stock to “overweight” and raised its price target to $60, citing strong server demand and progress in manufacturing. AMD rose 5.7%, while Nvidia slipped 0.2%. Susquehanna raised its Intel target to $40 but warned of PC and data center headwinds. Intel’s new 18A chips, launched at CES, will appear in over 200 PC models this month.
13 January 2026
····
SMCI stock slides after Goldman starts Super Micro at Sell and flags margin downside

SMCI stock slides after Goldman starts Super Micro at Sell and flags margin downside

Goldman Sachs assumed coverage of Super Micro Computer with a Sell rating and a $26 price target, citing shrinking margins and cash pressures amid rising AI-server competition. SMCI shares fell about 6% to $28.31 in late morning trade. Gross margins have contracted for nine quarters, and free cash flow was negative $950 million in Q1 fiscal 2026. Inventory rose to $5.7 billion, with the cash conversion cycle lengthening to 123 days.
13 January 2026
·
1 … 189 190 191 192 193 … 535

Stock Market Today

Strive Asset Management (ASST) stock price jumps after 1-for-20 reverse split — what investors watch next

7 February 2026
NEW YORK, Feb 7, 2026, 10:06 ET — Market closed. Shares of Strive, Inc. (ASST) jumped 20.8% on Friday and closed at $11.915, the first regular session after a 1-for-20 reverse stock split took effect ahead of the open. The stock ranged from $9.35 to $12.25, with 9.36 million shares traded, according to market data. (Investing.com) With U.S. markets shut for the weekend, the next test is Monday’s open: whether the higher share price brings in steadier buying, or just resets the tape for another bout of sharp swings. Reverse splits bundle shares — 20 become one — lifting the
Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Go toTop